Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Few potholes in WinRho's road

WASHINGTON - Despite what was described as suboptimal clinical study design, FDA officials supported Univax Biologics Inc.'s application for WinRho SD at an abbreviated advisory committee meeting last week.

The 1-1/2 hour meeting was held to allow the Blood Products Advisory Committee to discuss the application for treatment of idiopathic thrombocytopenic purpura (ITP), a bleeding disorder, and prevention of Rh isoimmunization. The members were not asked to vote

Read the full 681 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE